A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)

Paclitaxel is an agent widely used in second-line chemotherapy for advanced gastric cancer. The aim of this trial is to evaluate the efficacy and safety of 3-weekly or weekly doses of nanoparticle albumin-bound-paclitaxel compared with weekly doses of Cremophor-based paclitaxel in patients with unre...

Descripción completa

Detalles Bibliográficos
Autores principales: Koizumi, Wasaburo, Morita, Satoshi, Sakata, Yuh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Clinical Trial Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340275/
https://www.ncbi.nlm.nih.gov/pubmed/25516635
http://dx.doi.org/10.1093/jjco/hyu205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340275/
https://www.ncbi.nlm.nih.gov/pubmed/25516635
http://dx.doi.org/10.1093/jjco/hyu205

Ejemplares similares